Kura Oncology (KURA)

Jul 3, 2026, 7:30 AM EDT - 1 day ago

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 12, 2026, 8:00 AM EDT - 22 days ago

Kura Oncology Transcript: Status update

Jun 12, 2026, 8:00 AM EDT - 22 days ago

Kura Oncology Press release: Status update

Jun 12, 2026, 8:00 AM EDT - 22 days ago

Kura Oncology Slides: Status update

Jun 11, 2026, 8:02 AM EDT - 23 days ago

Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

Jun 3, 2026, 3:15 PM EDT - 4 weeks ago

Kura Oncology Transcript: Investor update

Jun 3, 2026, 3:15 PM EDT - 4 weeks ago

Kura Oncology Press release: Investor update

Jun 3, 2026, 3:15 PM EDT - 4 weeks ago

Kura Oncology Slides: Investor update

2026-06-03T11:45:26.000Z - 4 weeks ago

Kura reports data supporting darlifarnib potential for KRAS-mutant cancers

Jun 3, 2026, 6:53 AM EDT - 4 weeks ago

Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy

Jun 2, 2026, 8:32 AM EDT - 4 weeks ago

Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML

May 26, 2026, 1:30 PM EDT - 5 weeks ago

Kura Oncology Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 26, 2026, 8:00 AM EDT - 5 weeks ago

Kura Oncology Proxy statement: Proxy filing

2026-05-26T10:22:44.000Z - 5 weeks ago

Kura Oncology reports first-in-human data from the FIT-001 clinical trial

May 26, 2026, 6:02 AM EDT - 5 weeks ago

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

May 19, 2026, 4:02 PM EDT - 6 weeks ago

Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit

May 13, 2026, 6:00 PM EDT - 7 weeks ago

Kura Oncology Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T21:25:48.000Z - 7 weeks ago

Kura Oncology reports Q1 EPS (83c), consensus (78c)

May 12, 2026, 4:30 PM EDT - 7 weeks ago

Kura Oncology Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 7 weeks ago

Kura Oncology Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 7 weeks ago

Kura Oncology Quarterly report: Q1 2026

May 12, 2026, 4:02 PM EDT - 7 weeks ago

Kura Oncology Reports First Quarter 2026 Financial Results

May 12, 2026, 4:00 PM EDT - 7 weeks ago

Kura Oncology Slides: Corporate presentation

2026-05-12T19:13:17.000Z - 7 weeks ago

Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial

May 12, 2026, 9:40 AM EDT - 7 weeks ago

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

May 6, 2026, 7:30 AM EDT - 2 months ago

Kura Oncology to Participate in Bank of America Securities Healthcare Conference

May 5, 2026, 7:30 AM EDT - 2 months ago

Kura Oncology to Report First Quarter 2026 Financial Results

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

Apr 17, 2026, 10:30 AM EDT - 2 months ago

Kura Oncology Transcript: Investor Update

Apr 17, 2026, 10:30 AM EDT - 2 months ago

Kura Oncology Press release: Investor Update

Apr 17, 2026, 10:30 AM EDT - 2 months ago

Kura Oncology Slides: Investor Update

2026-04-17T10:06:05.000Z - 2 months ago

Kura Oncology reports results from ongoing FIT-001 clinical trial

Apr 17, 2026, 6:00 AM EDT - 2 months ago

Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

2026-04-14T11:42:35.000Z - 2 months ago

Kura Oncology initiated with a Buy at Lake Street

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Kura Oncology Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 3 months ago

Kura Oncology Proxy statement: Proxy filing

Apr 9, 2026, 7:30 AM EDT - 3 months ago

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

2026-03-30T13:08:09.000Z - 3 months ago

Syndax assumed with a Buy at Jefferies

SNDX

2026-03-24T15:07:11.000Z - 3 months ago

Kura Oncology price target lowered to $25 from $30 at Mizuho

2026-03-13T13:43:20.000Z - 4 months ago

Kura Oncology price target lowered to $15 from $16 at UBS

Mar 12, 2026, 9:00 AM EDT - 4 months ago

Kura Oncology Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 10:40 AM EDT - 4 months ago

Kura Oncology Transcript: Leerink Global Healthcare Conference 2026

2026-03-06T14:25:12.000Z - 4 months ago

Kura Oncology price target raised to $30 from $29 at BofA

2026-03-06T12:48:51.000Z - 4 months ago

Kura Oncology price target lowered to $36 from $38 at Wedbush

Mar 5, 2026, 8:00 AM EST - 4 months ago

Kura Oncology Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:00 AM EST - 4 months ago

Kura Oncology Annual report: Q4 2025

Mar 5, 2026, 8:00 AM EST - 4 months ago

Kura Oncology Earnings release: Q4 2025

Mar 5, 2026, 7:00 AM EST - 4 months ago

Kura Oncology Slides: Corporate presentation

2026-03-05T11:36:05.000Z - 4 months ago

Kura Oncology reports Q4 EPS (92c), consensus (49c)

Mar 5, 2026, 6:31 AM EST - 4 months ago

Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 4, 2026, 11:50 AM EST - 4 months ago

Kura Oncology Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-03T18:35:52.000Z - 4 months ago

Kura Oncology management to meet with Citizens

Feb 26, 2026, 7:30 AM EST - 4 months ago

Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results

Feb 25, 2026, 7:30 AM EST - 4 months ago

Kura Oncology to Participate in Three Upcoming Investor Conferences

2026-02-03T11:50:13.000Z - 5 months ago

Kura Oncology price target lowered to $29 from $30 at BofA

Jan 11, 2026, 5:00 PM EST - 6 months ago

Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones

Dec 8, 2025, 12:30 PM EST - 7 months ago

Kura Oncology Transcript: Status Update

Dec 8, 2025, 12:30 PM EST - 7 months ago

Kura Oncology Press release: Status Update

Dec 8, 2025, 12:30 PM EST - 7 months ago

Kura Oncology Slides: Status Update

Dec 8, 2025, 10:30 AM EST - 7 months ago

Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML

Dec 3, 2025, 8:32 AM EST - 7 months ago

Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia

Dec 2, 2025, 8:02 AM EST - 7 months ago

First U.S. Commercial Sale of KOMZIFTI™ Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin

Nov 25, 2025, 5:16 PM EST - 7 months ago

KOMZIFTI™ (ziftomenib) Added to National Comprehensive Cancer Network® (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

Nov 19, 2025, 10:30 AM EST - 8 months ago

Kura Oncology Transcript: Jefferies London Healthcare Conference 2025

Nov 13, 2025, 12:30 PM EST - 8 months ago

Kura Oncology Transcript: FDA Announcement

Nov 13, 2025, 12:30 PM EST - 8 months ago

Kura Oncology Press release: FDA Announcement

Nov 13, 2025, 10:51 AM EST - 8 months ago

Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI™ (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

Nov 13, 2025, 10:32 AM EST - 8 months ago

US FDA approves Kura Oncology's blood cancer therapy

Nov 12, 2025, 4:05 PM EST - 8 months ago

Kura Oncology to Participate in Upcoming Investor Conference

Nov 4, 2025, 8:00 AM EST - 8 months ago

Kura Oncology Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

Kura Oncology Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 8 months ago

Kura Oncology Earnings release: Q3 2025

Nov 4, 2025, 6:31 AM EST - 8 months ago

Kura Oncology Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 4:02 PM EST - 8 months ago

Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin

Nov 3, 2025, 9:14 AM EST - 8 months ago

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

Oct 28, 2025, 4:01 PM EDT - 8 months ago

Kura Oncology to Report Third Quarter 2025 Financial Results

Oct 24, 2025, 7:02 AM EDT - 9 months ago

Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin

Oct 18, 2025, 1:30 PM EDT - 9 months ago

Kura Oncology Transcript: ESMO Congress 2025

Oct 18, 2025, 1:30 PM EDT - 9 months ago

Kura Oncology Slides: FY 2025

Oct 18, 2025, 3:23 AM EDT - 9 months ago

Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 1, 2025, 2:30 PM EDT - 9 months ago

Kura Oncology Transcript: UBS Virtual Oncology Day

Oct 1, 2025, 7:01 AM EDT - 9 months ago

Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Sep 29, 2025, 4:01 PM EDT - 9 months ago

Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML)

Sep 25, 2025, 5:18 PM EDT - 10 months ago

Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology

Sep 16, 2025, 4:30 PM EDT - 10 months ago

Kura Oncology Transcript: Study Update

Sep 16, 2025, 4:30 PM EDT - 10 months ago

Kura Oncology Press release: Study Update

Sep 16, 2025, 4:30 PM EDT - 10 months ago

Kura Oncology Slides: Study Update

Sep 16, 2025, 4:01 PM EDT - 10 months ago

Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types

Sep 10, 2025, 1:50 PM EDT - 10 months ago

Kura Oncology Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 1:00 PM EDT - 10 months ago

Kura Oncology Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 7, 2025, 6:00 PM EDT - 10 months ago

Kura Oncology Slides: Corporate Presentation

Sep 4, 2025, 8:35 AM EDT - 10 months ago

Kura Oncology Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 8:02 AM EDT - 10 months ago

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Kura Oncology Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Kura Oncology Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 11 months ago

Kura Oncology Earnings release: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 11 months ago

Kura Oncology Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Kura Oncology to Report Second Quarter 2025 Financial Results

Jun 18, 2025, 4:30 PM EDT - 1 year ago

Kura Oncology Transcript: Status Update

Jun 18, 2025, 4:30 PM EDT - 1 year ago

Kura Oncology Slides: Status Update

Jun 12, 2025, 7:30 AM EDT - 1 year ago

Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

Jun 10, 2025, 11:20 AM EDT - 1 year ago

Kura Oncology Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 2:35 PM EDT - 1 year ago

Kura Oncology Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 7:30 PM EDT - 1 year ago

Kura Oncology Transcript: American Society of Clinical Oncology (ASCO) Annual Meeting 2025

Jun 2, 2025, 7:30 PM EDT - 1 year ago

Kura Oncology Slides: FY 2025

Jun 2, 2025, 6:00 PM EDT - 1 year ago

Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

Jun 1, 2025, 7:00 PM EDT - 1 year ago

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

May 27, 2025, 9:00 AM EDT - 1 year ago

Kura Oncology Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 22, 2025, 5:30 PM EDT - 1 year ago

Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting

May 14, 2025, 10:00 AM EDT - 1 year ago

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

May 13, 2025, 6:00 PM EDT - 1 year ago

Kura Oncology Transcript: BofA Securities 2025 Healthcare Conference

May 1, 2025, 4:30 PM EDT - 1 year ago

Kura Oncology Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Kura Oncology Quarterly report: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Kura Oncology Earnings release: Q1 2025

May 1, 2025, 4:05 PM EDT - 1 year ago

Kura Oncology Reports First Quarter 2025 Financial Results

May 1, 2025, 7:00 AM EDT - 1 year ago

Kura Oncology Slides: Corporate Presentation

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

Apr 24, 2025, 7:30 AM EDT - 1 year ago

Kura Oncology to Report First Quarter 2025 Financial Results

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Kura Oncology Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Kura Oncology Proxy statement: Proxy Filing

Apr 8, 2025, 10:30 AM EDT - 1 year ago

Kura Oncology Transcript: Stifel 2025 Virtual Targeted Oncology Forum

Apr 8, 2025, 7:30 AM EDT - 1 year ago

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Kura Oncology to Participate in Stifel Targeted Oncology Forum

Mar 26, 2025, 7:30 AM EDT - 1 year ago

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Kura Oncology Transcript: Leerink Global Healthcare Conference 2025

Mar 11, 2025, 9:30 AM EDT - 1 year ago

Kura Oncology Transcript: Barclays 27th Annual Global Healthcare Conference

Mar 4, 2025, 2:30 PM EST - 1 year ago

Kura Oncology Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 26, 2025, 4:30 PM EST - 1 year ago

Kura Oncology Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Kura Oncology Annual report: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Kura Oncology Earnings release: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

Kura Oncology Slides: Q4 2024

Feb 26, 2025, 4:03 PM EST - 1 year ago

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 7:30 AM EST - 1 year ago

Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results